利索-全球专利检索

  1. 登录
  2. 注册
发明授权
US4806545A (-)-1.beta.-ethyl-1.alpha.-hydroxymethyl-1,2,3,4,6,7,12, 12B.alpha.-octahydroindolo(2,3-A)quinolizine, process for its preparation and pharmaceutical compositions containing same 失效
（ - ） - 1β-乙基-1α-羟甲基-1,2,3,4,6,7,12,12aαα-八氢吲哚（2,3-A）喹嗪，其制备方法和含有它们的药物组合物

(-)-1.beta.-ethyl-1.alpha.-hydroxymethyl-1,2,3,4,6,7,12, 12B.alpha.-octahydroindolo(2,3-A)quinolizine, process for its preparation and pharmaceutical compositions containing same
摘要：
The invention relates to the new (-)-1.beta.-ethyl-1.alpha.-hydroxymethyl-1,2, 3,4,6,7,12,12b.alpha.-octa-hydroindolo[2,3-a] quinolizine of the formula (I) ##STR1## and acid addition salts thereof. According to another aspect of the invention there is provided a process for the preparation of the compound of formula (I) and acid addition salts thereof by resolution of the corresponding racemic compound and optionally by subsequent hydrolysis and/or salt formation.The compound of formula (I) shows a remarkable peripheral vasodilating and antihypoxial activity. Pharmaceutical compositions comprising it as active ingredient are also within the scope of the invention.
摘要（中）：

本发明涉及新的（ - ） - 1β-乙基-1α-羟基甲基-1,2,3,4,6,7,12,12bα-正 - 氢吲哚并[2,3-a]喹嗪 式（I）化合物（I）及其酸加成盐。 根据本发明的另一方面，提供了通过拆分相应的外消旋化合物和任选地随后的水解和/或盐形成来制备式（I）化合物及其酸加成盐的方法。 式（I）化合物显示出显着的外周血管扩张和抗低氧活性。 包含其作为活性成分的药物组合物也在本发明的范围内。

公开/授权文献
信息查询
Global Dossier Espacenet
0/0